Fenofibrate for Cardiovascular Disease Prevention in Metabolic Syndrome and Type 2 Diabetes Mellitus

American Journal of Cardiology

Volumn 102, Issue 12 SUPPL., 2008, Pages 28L-33L

  Steiner, George ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; ATORVASTATIN PLUS FENOFIBRATE; FENOFIBRATE; FENOFIBRATE PLUS FLUINDOSTATIN; FENOFIBRATE PLUS SIMVASTATIN; FLUINDOSTATIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLACEBO; SIMVASTATIN; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETIC MICROANGIOPATHY; DRUG ACTIVITY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DYSLIPIDEMIA; HUMAN; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FENOFIBRATE; HUMANS; HYPOLIPIDEMIC AGENTS; METABOLIC SYNDROME X; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS;

EID: 57649086237     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.09.072     Document Type: Article

References (31)

1. Chapman M.J. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 171 (2003) 1-13
2. Keating G.M., and Croom K.F. Fenofibrate: a review of its use in primary dyslipidemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 67 (2007) 121-153
3. Fazio S., and Linton M.F. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr Atheroscler Rep 6 (2004) 148-157
4. Brown J.D., and Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 115 (2007) 518-533
5. Schoonjans K., Staels B., and Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 37 (1996) 907-925
6. Vakkilainen J., Steiner G., Ansquer J.C., Aubin F., Rattier S., Foucher C., Hamsten A., Taskinen M.R., and DAIS Group. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Study (DAIS). Circulation 107 (2003) 1733-1737
7. Ridker P.M. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 49 (2007) 2129-2138
8. Haffner S.M. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 97 suppl (2006) 3A-11A
9. Mertens I., and Van Gaal L.F. New International Diabetes Federation (IDF) and National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII) criteria and the involvement of hemostasis and fibrinolysis in the metabolic syndrome. J Thromb Haemost 4 (2006) 1164-1166
10. Zambon A., Gervois P., Pauletto P., Fruchart J.C., and Staels B. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPARα activators: clinical and experimental evidence. Arterioscler Thromb Vasc Biol 26 (2006) 977-986
11. Okopien B., Krysiak R., and Herman Z.S. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab 91 (2006) 1770-1778
12. Babaev V.R., Yancey P.G., Ryzhov S.V., Kon V., Breyer M.D., Magnuson M.A., Fazio S., and Linton M.F. Conditional knockout of macrophage PPARγ increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 25 (2005) 1647-1653
13. Idzior-Waldus B., Sieradzki J., Rostworowski W., Zdzienicka A., Kawalec E., Wojcik J., Zarnecki A., and Blane G. Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. Eur J Clin Invest 30 (2000) 871-878
14. Kon Koh K., Yeal Ahn J., Hwan Han S., Kyu Jin D., Sik Kim H., Cheon Lee K., Kyun Shin E., and Sakuma I. Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis. Atherosclerosis 174 (2004) 379-383
15. Muhlestein J.B., May H.T., Jensen J.R., Horne B.D., Lanman R.B., Lavasani F., Wolfert R.L., Pearson R.R., Yannicelli H.D., and Anderson J.L. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol 48 (2006) 396-401
16. Playford D.A., Watts G.F., Best J.D., and Burke V. Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus. Am J Cardiol 90 (2002) 1254-1257
17. Davidson M. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. Am J Cardiol suppl (2008) 19L-27L
18. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation 106 (2002) 3143-3421
19. Grundy S.M., Hansen B., Smith Jr. S.C., Cleeman J.I., Kahn R.A., American Heart Association, National Heart, Lung, and Blood Institute, and American Diabetes Association. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association Conference on scientific issues related to management. Circulation 109 (2004) 551-556
20. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 31 (2008) S12-S54
21. Koh K.K., Quon M.J., Han S.H., Chung W.J., Ahn J.Y., Seo Y.H., Choi I.S., and Shin E.K. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 45 (2005) 1649-1653
22. Davidson M.H., Bays H., Rhyne J., Stein E., Rotenberg K., and Doyle R. Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8 week, randomized, double-blind, placebo-controlled study. Clin Ther 27 (2005) 715-727
23. Derosa G., Cicero A.E., Bertone G., Piccinni M.N., Ciccarelli L., and Roggeri D.E. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clin Ther 26 (2004) 1599-1607
24. Athyros V.G., Papageorgiou A.A., Athyrou V.V., Demitriadis D.S., and Kontopoulos A.G. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 25 (2002) 1198-1202
25. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes; the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357 (2001) 905-910
26. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., Forder P., Pillai A., Davis T., Glosziou P., et al., FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD trial): randomised controlled trial. Lancet 366 (2005) 1849-1861
27. Sacks F.M. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study: implications for fenofibrate. Am J Cardiol suppl (2008) 34L-40L
28. Ingelsson E., Sullivan L.M., Murabito J.M., Fox C.S., Benjamin E.J., Polak J.F., Meigs J.B., Keyes M.J., O'Donnell C.J., Wang T.J., et al. Prevalence and prognostic impact of subclinical cardiovascular disease in individuals with the metabolic syndrome and diabetes. Diabetes 56 (2007) 1718-1726
29. Ansquer J.C., Foucher C., Rattier S., Taskinen M.R., and Steiner G. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DIAS). Am J Kidney Dis 45 (2005) 485-493
30. Keech A.C., Mitchell P., Summanen P.A., O'Day J., Davis T.M., Moffitt M.S., Taskinen M.R., Simes R.J., Tse D., Williamson E., et al., FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370 (2007) 1687-1697
31. Burgess D., Hunt D., Li L.P., Zhang J., Sy R., Laakso M., Davis T., Colman P., Forder P., Williamson E., Pike R., Keech A., and FIELD Investigators. Effects of fenofibrate on silent myocardial infarction, hospitalization for acute coronary syndromes and amputation in type 2 diabetes: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study [abstract]. Circulation 116 (2007) II-838